Author(s):
N. Madhavi, A. Nikitha, M. Sreeja, T. Rama Rao
Email(s):
madhavi@cmrcp.ac.in
DOI:
10.52711/0975-4377.2025.00020 
Address:
N. Madhavi1, A. Nikitha2, M. Sreeja3, T. Rama Rao4
1,2,3Department of Pharmaceutics, CMR College of Pharmacy, Medchal, Kandlakoya, Hyderabad - 501401.
4Principal and Professor, Department of Pharmaceutics, CMR College of Pharmacy, Medchal, Kandlakoya, Hyderabad - 501401.
*Corresponding Author
Published In:
Volume - 17,
Issue - 2,
Year - 2025
ABSTRACT:
When personalised medicine offers patients individualised therapies, it has completely changed the healthcare industry. However, access to customised pharmaceuticals is frequently a difficulty for particular populations, including paediatrics, the elderly, and individuals with rare disorders. In order to overcome these obstacles, three-dimensional (3D) printing technology has become a viable option. In order to give a comprehensive picture of the current status of 3D printing technology in personalised medicine, this study will concentrate on its uses, advantages, and drawbacks in particular populations. Personalised pharmaceutical items, including tablets, capsules, and implants, are manufactured using a variety of 3D printing methods, materials, and software. The review emphasises how 3D printing technology can be used to better therapeutic outcomes for particular populations, decrease side effects, and improve drug adherence. In addition, we list the economic, technological, and regulatory barriers that must be overcome in order to promote the broad use of 3D printing in personalised medicine. A thorough framework for comprehending how 3D printing technology is transforming personalised treatment for particular populations is offered by this review.
Cite this article:
N. Madhavi, A. Nikitha, M. Sreeja, T. Rama Rao. A Review on 3D Printing Technology: Personalized Medicine for Special Population. Research Journal of Pharmaceutical Dosage Forms and Technology. 2025; 17(2):137-2. doi: 10.52711/0975-4377.2025.00020
Cite(Electronic):
N. Madhavi, A. Nikitha, M. Sreeja, T. Rama Rao. A Review on 3D Printing Technology: Personalized Medicine for Special Population. Research Journal of Pharmaceutical Dosage Forms and Technology. 2025; 17(2):137-2. doi: 10.52711/0975-4377.2025.00020 Available on: https://rjpdft.com/AbstractView.aspx?PID=2025-17-2-8
REFERENCES:
1. Bethany C.G, Jayda L.E, Sarah Y.L, Chengpeng C, Dana M.S. Evaluation of 3D Printing and Its Potential Impact on Biotechnology and the Chemical Sciences. Anal. Chem. 2014, 86, 3240–3253.
2. Ishita M, Gurvinder K, Amir S, Aneesah, M.; Cato, T.L. Progress in 3D Bioprinting Technology for Tissue/Organ Regenerative Engineering. Biomaterials. 2020; 226: 119536.
3. Jimenez M, Romero L, Dominguez I A, del Mar Espinosa M, Domínguez M. Additive Manufacturing Technologies: An Overview about 3D Printing Methods and Future Prospects. Complexity. 2019; 2019: 1–30.
4. Holzmann P, Breitenecker RJ, Soomro AA, Schwarz EJ. User entrepreneur business models in 3D printing. J ManufTechnolManag. 2017; 28:75–94.
5. Computer Sciences Corporation. 3D printing and the future of manufacturing. Tysons (VA): The Corporation; 2012.
6. Konta A, Garcia-Pina M, Serrano D. Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful Bioengineering. 2017; 4: 79.
7. Nguyen V.V.T, Ye S, Gkouzioti V, van Wolferen M.E, Yengej F.Y et al. A human kidney and liver organoid-based multi-organ-on-a-chip model to study the therapeutic effects and biodistribution of mesenchymal stromal cell-derived extracellular vesicles. J. Extracell. Vesicles. 2022; 11: e12280.
8. European Commission Personalised Medicines. Available online: https://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en (accessed on 9 November 2022).
9. Nimmesgern E, Norstedt I, Draghia-Akli R. Enabling personalized medicine in Europe by the European Commission’s funding activities. Pers Med. 2017; 14: 355–365.
10. Don W, Lauren B, Kelly C. A chieving high dose drug load with rapid dispersion using 3D printing. ApreciaZipdose. 2014.
11. Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D printed dosage forms: Opportunities and challenges. Pharm Res. 2016;33(8):1817-32.
12. Giangreco NP, Elias JE, Tatonetti NP. No Population Left behind: Improving Paediatric Drug Safety Using Informatics and Systems Biology. Br J Clin Pharmacol. 2022; 88: 464–1470.
13. Shibata Y, Itoh H, Matsuo H, Nakajima K. Differences in Pharmaceutical Intervention Triggers for the Optimization of Medication by Patient Age: A University Hospital Study. Biol Pharm Bull. 2021; 44: 1060–1066.
14. Aho J, Bøtker JP, Genina N, Edinger M, Arnfast L, Rantanen J. Roadmap to 3D-printed oral pharmaceutical dosage forms: feedstock filament properties and characterization for fused deposition modeling. J Pharm Sci. 2019; 108:26–35.
15. Jamroz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical and medical applications – recent achievements and challenges. Pharm Res. 2018; 35:176.
16. M. Preis, H. Oblom 3D-Printed drugs for children are we ready yet? AAPS PharmSciTech. 2017; 18 (2): 303-308.
17. DA. VanRietNales, BJ deNeef, AF. Schobben, JA. Ferreira, TCG Egberts, CMA Rademaker Acceptability of different oral formulations in infants and preschool children. Archives of Disease in Childhood. 2013; 98 (9):725-731.
18. H. oblom, E. Sjoholm, M. Rautamo, N. Sandler Towards printed pediatric medicines in hospital pharmacies: comparison of 2D and 3D-printed orodispersible warfarin films with conventional oral powders in unit dose sachets. Pharmaceutics. 2019; 11 (7): 334.
19. A Goyanes, CM. Madla A, Umerji G. DuranPineiro JM. Giraldez Montero MJ. Lamas Diaz et al. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patients. Int J Pharm. 2019; 567: 118497.
20. DG. Yu, XX. Shen C. LM Zhu K. White XL Yang. Novel oral fast-disintegrating drug delivery devices with predefined inner structure fabricated by Three-Dimensional Printing. J Pharm Pharmacol. 2009; 61 (3): 323-329.
21. HG. Yi, YJ. Choi KS. Kang. et al. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression J Contr Release. 2016; 238: 231-241.
22. PR. Martinez, A. Goyanes, AW. Basit S. Gaisford Fabrication of drug-loaded hydrogels with stereolithographic 3D printing. Int J Pharm. 2017; 532 (1): 313-317.
23. N. Genina, J. Hollander, H. Jukarainen, E. Makila, J. Salonen, N. Sandler Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devices.
24. Hull CW. Apparatus for Production of Three-Dimensional Objects by Stereolithography. U.S. Patent 4575330, 1986.
25. Vaz VM, Kumar L. 3D printing as a promising tool in personalized medicine. AAPS PharmSciTech.2021;22:49.96.
26. Cummings D. Prosthetics in the developing world: a review of the literature. Prosthet Orthot Int.1996; 20:51–60.
27. Barcik J, Ernst M, Schwyn R, Freitag L, Dlaska CE, Drenchev L, et al. Development of surgical tools and Procedures for experimental preclinical surgery using computer simulations and 3D printing. Int JOnline Biomed Eng. 2020; 16:183–95
28. Rittel D, Shemtov-Yona K, Lapovok R. Random spectrum fatigue performance of severely plastically Deformed titanium for implant dentistry applications. J MechBehav Biomed Mater. 2018; 83:94–101.
29. Schlegel L, Ho M, Fields JM, Backlund E, Pugliese R, Shine KM. Standardizing evaluation of patient specific 3D printed models in surgical planning: development of a cross-disciplinary survey tool for Physician and trainee feedback. BMC Med Educ. 2022; 22:614.
30. Bracaglia LG, Messina MJ, Winston S, Kuo C-Y, LermanM, Fisher JP. Printed pericardium hydrogels to promote wound healing in vascular applications. Biomacromolecules. 2017;18(11):3802–11.
31. Awad A, Fina F, Trenfield SJ, Patel P, Goyanes A, Gaisford S, et al. 3D printed pellets (miniprintlets): a novel, multi-drug, controlled release platform technology. Pharmaceutics. 2019; 11:148.
32. Pelkonen O. Metabolism and Pharmacokinetics in Children and the Elderly. Expert Opin. Drug Metab. Toxicol. 2007; 3: 147–148.
33. Pratico AD, Longo L, Mansueto S, Gozzo L, Barberi I. et al. Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study. Curr Drug Saf. 2018; 13: 200–207.